Often big dreams are visualised inside tiny rooms. This is one such story of how two dreamer friends, Hitesh Goswami and Kshitij Rishi, went all in to change how India fights cancer.
Hitesh had worked for years in the world of biotech. One burning question kept bothering him: Why should Indian cancer patients settle for treatments based on Western genetic data?
That question led to the birth of 4baseCare, a precision oncology company that studies evidence generated from real-world settings, accelerates cancer research and improves clinical outcomes. Built for India, from India, their mission is to make sure every person gets treatment that’s made for them, not based on generic global data.
At its core lies TARGT Indiegene: India’s first population-specific cancer gene panel, and SoLiQ, a next-gen hybrid biopsy solution. Together, they offer a 360° view of a patient’s cancer, enabling oncologists to personalize treatment like never before.
Apart from this, to focus more on the human side of care, they launched OncoBuddy, a platform that supports patients not just medically, but emotionally. From mental health to nutrition advice, it’s a one-stop space for people to feel heard and cared for.
From early support under Karnataka’s Elevate program to becoming the first Asia-Pacific company in the Illumina Accelerator, the startup’s journey has been steeped in ambition, science, and soul. Today, they’re backed by Infosys, Yali Capital, and global biotech leaders—proof that deep tech rooted in empathy can turn heads and change the game.
Today, 4baseCare has grown into a team of 150+, with labs across India and even in Dubai. They’ve raised millions in funding and run over 1,000 tests a month. But at heart, their mission remains simple: make cancer care more personal, more local, and more kind.
They have unified doctors, scientists, and engineers, with one goal: “Together, We Beat Cancer.”
Written By:
Yashi Bhatia
